Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fenoldopam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 known ✓ | P21728 | 16/20 | 1.00 |
| ▸ | DRD2 | P14416 | 9/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | RECQL | P46063 | 4/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | KDM1A | O60341 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fenoldopam SCHEMBL34250 | 1.00 | DRD1 (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL13287212 | 1.00 | DRD1 (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL1815791 | 1.00 | DRD1 (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL41214 | 1.00 | DRD1 (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL1319766 | 0.99 | KDM4E (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL29424282 | 0.99 | DRD1 (0.97) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL9157381 | 0.99 | DRD1 (0.97) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL11215595 | 0.99 | KDM4E (1.00) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL16241872 | 0.99 | DRD1 (0.97) | DRD1DRD2KDM4ERECQLBLM | |
| Fenoldopam SCHEMBL3136078 | 0.94 | GFER (0.91) | DRD1DRD2KDM4ERECQLBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3990026-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | Serina Therapeutics, Inc. (US) | 2022-05-04 | — | — | EP | claimed |
| CN-114258309-A | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | 塞瑞纳治疗公司 | 2022-03-29 | — | — | CN | claimed |
| EP-0160513-B1 | FENOLDOPAM 4', 8-BIS-HYDROGEN SULFATES | SMITHKLINE BECKMAN CORPORATION (US) | 1987-09-16 | — | — | EP | claimed |
| EP-0160513-A1 | Fenoldopam 4', 8-bis-hydrogen sulfates | SMITHKLINE BECKMAN CORPORATION (US) | 1985-11-06 | — | — | EP | claimed |
| EP-0087319-A1 | R- and S-isomers of 6-chloro-7,8-dihydroxy-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine | SMITHKLINE BECKMAN CORPORATION (US) | 1983-08-31 | — | — | EP | claimed |
| US-20250262268-A1 | Methods and Compositions for Inhibiting Viral Infection | NEW YORK UNIVERSITY | 2025-08-21 | — | — | US | disclosed |
| CN-120154736-A | Cleavable conjugates of catechol compounds and water-soluble polymers and methods of treatment using the same | 塞瑞纳治疗阿拉巴马公司 | 2025-06-17 | — | — | CN | disclosed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | TUFTS MEDICAL CENTER (US) | 2024-08-13 | — | — | US | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
| CN-114258309-A | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | 塞瑞纳治疗公司 | 2022-03-29 | — | — | CN | disclosed |
| US-8822442-B2 | Somatostatin-dopamine chimeric analogs | IPSEN PHARMA S.A.S. (FR) | 2014-09-02 | — | — | US | disclosed |
| US-8822442-B2 | Somatostatin-dopamine chimeric analogs | IPSEN PHARMA S.A.S. (FR) | 2014-09-02 | — | — | US | disclosed |
| EP-0380355-B1 | Carbamates of 6-chloro-7,8-dihydroxy-1-(4'-Hydroxyphenyl)-2,3,4,5-tetra-hydro-1H-3-benzazepine as prodrugs | SMITHKLINE BEECHAM CORP (US) | 1995-01-11 | — | — | EP | disclosed |
| EP-0380355-A2 | Carbamates of 6-chloro-7,8-dihydroxy-1-(4'-Hydroxyphenyl)-2,3,4,5-tetra-hydro-1H-3-benzazepine as prodrugs | SMITHKLINE BEECHAM CORPORATION (US) | 1990-08-01 | — | — | EP | disclosed |
| US-4861771-A | Carbamates of 6-chloro-7,8-dihydroxy-1-(4'-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine as prodrugs | SMITHKLINE BECKMAN CORPORATION (US) | 1989-08-29 | — | — | US | disclosed |
| EP-0160513-B1 | FENOLDOPAM 4', 8-BIS-HYDROGEN SULFATES | SMITHKLINE BECKMAN CORPORATION (US) | 1987-09-16 | — | — | EP | disclosed |
| EP-0160513-A1 | Fenoldopam 4', 8-bis-hydrogen sulfates | SMITHKLINE BECKMAN CORPORATION (US) | 1985-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | DRD1 4073/4885DRD2 3481/4885KDM4E 4313/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | DRD1 4073/4885DRD2 3481/4885KDM4E 4313/4885 |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | LIPG, CD40, LDLR | DRD1 4436/4885DRD2 4173/4885KDM4E 3386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.